Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
December is bringing more than holiday stress—mortgage rates are climbing as the Federal Reserve delivers mixed signals and key economic reports face delays. After sharp swings in November, analysts expect rates to rise through the month, with internal disagreements among Fed members adding to the turbulence. As lenders recalibrate their expectations for early 2026, buyers and industry professionals should brace for rapid, unpredictable rate movements.
Artificial intelligence is rapidly transforming how real estate professionals work, and this week’s updates highlight just how fast the tech is evolving. Rechat’s new integration with Follow Up Boss streamlines CRM, marketing, and communication into one powerful workflow. RealScout has introduced an AI‑driven search tool built specifically for agents, delivering precise results from natural language prompts. Meanwhile, UtahRealEstate.com has launched AI voice search for consumers, offering real‑time conversational home‑finding. Together, these advancements signal a new era of efficiency and opportunity for both new and seasoned real estate professionals.
The Government Accountability Office is urging the FHFA to issue clear, updated guidance for Fannie Mae and Freddie Mac as AI‑driven tools reshape the mortgage industry. With automated valuations, underwriting systems, and algorithmic advertising carrying risks of embedded bias, regulators fear that fast‑moving proptech innovations may unintentionally reinforce past discrimination. The call for action comes as federal oversight shifts and industry professionals face growing pressure to stay compliant in an increasingly digital housing market.
Florida’s real estate and insurance sectors are undergoing major end‑of‑year shifts, from new AI oversight proposals and cooling housing markets to rising insurance premiums and transformative housing legislation. With inventory changes, pricing corrections, and new educational opportunities emerging across the state, professionals and students alike can use these insights to stay ahead in a rapidly evolving 2025–2026 landscape.
New analysis shows that eliminating property taxes in Florida—an idea promoted by Governor Ron DeSantis—could instantly raise home prices by 7 to 9 percent. While current homeowners may welcome the boost, experts warn it would worsen the state’s affordability crisis and shift tax burdens elsewhere, making it harder for future buyers and first‑time homeowners to enter the market.
Cyprus is rolling out sweeping housing and construction reforms, including fast‑track permits, incentives for affordable development, and a push for EU‑wide housing strategy. With single‑ and two‑family home approvals targeted at 40 days and apartment buildings at 80, the nation is tackling delays and boosting supply—offering insights and parallels for U.S. real estate and development professionals watching global trends.
